These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27208827)

  • 1. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry.
    Pellock JM; Faught E; Foroozan R; Sergott RC; Shields WD; Ziemann A; Lee D; Dribinsky Y; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Jul; 60():174-180. PubMed ID: 27208827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sabril® registry 5-year results: Characteristics of adult patients treated with vigabatrin.
    Krauss G; Faught E; Foroozan R; Pellock JM; Sergott RC; Shields WD; Ziemann A; Dribinsky Y; Lee D; Torri S; Othman F; Isojarvi J
    Epilepsy Behav; 2016 Mar; 56():15-9. PubMed ID: 26807550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Balancing clinical benefits of vigabatrin with its associated risk of vision loss.
    Pellock JM
    Acta Neurol Scand Suppl; 2011; (192):83-91. PubMed ID: 22061183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.
    Tolman JA; Faulkner MA
    Expert Opin Pharmacother; 2009 Dec; 10(18):3077-89. PubMed ID: 19954276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience.
    Schwarz MD; Li M; Tsao J; Zhou R; Wu YW; Sankar R; Wu JY; Hussain SA
    Epilepsy Behav; 2016 Apr; 57(Pt A):29-33. PubMed ID: 26921595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vigabatrin: 2008 update.
    Willmore LJ; Abelson MB; Ben-Menachem E; Pellock JM; Shields WD
    Epilepsia; 2009 Feb; 50(2):163-73. PubMed ID: 19230067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding and interpreting vision safety issues with vigabatrin therapy.
    Plant GT; Sergott RC
    Acta Neurol Scand Suppl; 2011; (192):57-71. PubMed ID: 22061181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Registry initiated to characterize vision loss associated with vigabatrin therapy.
    Pellock JM; Faught E; Sergott RC; Shields WD; Burkhart GA; Krauss GL; Foroozan R; Wesche DL; Weinberg MA
    Epilepsy Behav; 2011 Dec; 22(4):710-7. PubMed ID: 21978471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vigabatrin for infantile spasms.
    Pesaturo KA; Spooner LM; Belliveau P
    Pharmacotherapy; 2011 Mar; 31(3):298-311. PubMed ID: 21361740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical profile and treatment of infantile spasms using vigabatrin and ACTH--a developing country perspective.
    Ibrahim S; Gulab S; Ishaque S; Saleem T
    BMC Pediatr; 2010 Jan; 10():1. PubMed ID: 20078871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vigabatrin in Japanese patients with infantile spasms: Primary short-term study and extension study.
    Ohtsuka Y
    Epilepsy Behav; 2018 Jan; 78():134-141. PubMed ID: 29190579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of vigabatrin in childhood seizure disorders: results from a clinical audit.
    Prasad AN; Penney S; Buckley DJ
    Epilepsia; 2001 Jan; 42(1):54-61. PubMed ID: 11207785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A risk-benefit assessment of treatments for infantile spasms.
    Nabbout R
    Drug Saf; 2001; 24(11):813-28. PubMed ID: 11665869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primer on visual field testing, electroretinography, and other visual assessments for patients treated with vigabatrin.
    Sergott RC; Westall CA
    Acta Neurol Scand Suppl; 2011; (192):48-56. PubMed ID: 22061180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal structure and function in vigabatrin-treated adult patients with refractory complex partial seizures.
    Sergott RC; Johnson CA; Laxer KD; Wechsler RT; Cherny K; Whittle J; Feng G; Lee D; Isojarvi J
    Epilepsia; 2016 Oct; 57(10):1634-1642. PubMed ID: 27580566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.
    Lux AL; Edwards SW; Hancock E; Johnson AL; Kennedy CR; Newton RW; O'Callaghan FJ; Verity CM; Osborne JP;
    Lancet Neurol; 2005 Nov; 4(11):712-7. PubMed ID: 16239177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of West syndrome].
    Cvitanović-Sojat L; Gjergja R; Sabol Z; Hajnzić TF; Sojat T
    Acta Med Croatica; 2005; 59(1):19-29. PubMed ID: 15813352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-vision adverse events with vigabatrin therapy.
    Walker SD; Kälviäinen R
    Acta Neurol Scand Suppl; 2011; (192):72-82. PubMed ID: 22061182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group.
    Bruni J; Guberman A; Vachon L; Desforges C
    Seizure; 2000 Apr; 9(3):224-32. PubMed ID: 10777431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vigabatrin pediatric dosing information for refractory complex partial seizures: results from a population dose-response analysis.
    Nielsen JC; Tolbert D; Patel M; Kowalski KG; Wesche DL
    Epilepsia; 2014 Dec; 55(12):e134-8. PubMed ID: 25311090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.